Bcl-2 Protein and Photodynamic Therapy in Early Bronchial Cancer
Author Information
Author(s): Kawaguchi T, Yamamoto S, Naka N, Okishio K, Atagi S, Ogawara M, Hosoe S, Kawahara M, Furuse K
Primary Institution: National Kinki Central Hospital for Chest Diseases
Hypothesis
The expression of bcl-2 protein is related to local recurrence after photodynamic therapy in early squamous cell carcinoma of the bronchus.
Conclusion
The study found that bcl-2 expression was not associated with the cure rate from photodynamic therapy, but tumor size and T status were significant predictors of cure.
Supporting Evidence
- 43 lesions achieved complete response after photodynamic therapy.
- 31 carcinomas resulted in a cure, defined as no recurrence after 2 years.
- Bcl-2 immunoreactivity was detected in 46.9% of tumors.
- Large tumors expressed more bcl-2 protein than small tumors.
- T status was the only predictor of cure according to multivariate analysis.
Takeaway
This study looked at how a protein called bcl-2 affects the chances of getting better after a specific cancer treatment, and it found that the size of the tumor is more important than the protein.
Methodology
Immunohistochemical analysis of bcl-2 and p53 protein expression in tumors from patients treated with photodynamic therapy.
Limitations
The study did not document the relationship between oncoprotein expression and local recurrence.
Participant Demographics
Patients with early squamous cell carcinoma of the bronchus treated from 1983 to 1997.
Statistical Information
P-Value
0.0155
Statistical Significance
p=0.008
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website